Court construed the oxybutynin release rate limitations of the ' 355 patent claims as ' in vivo release rates, that is, drug release in a human body ' or release in the gastrointestinal (GI) tract of a patient. Id . at 721.
On 8th October, 2004, Mylan fi led a motion for summary judgment of non-infringement of the ' 006 patent. The District Court held a Markman hearing in May 2005 to construe the claims of the ' 006 patent. Mylan argued
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.